Results 101 to 110 of about 73,703 (332)

COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES

Фармакоэкономика, 2015
a total of 62 patients with a diagnosis of low back pain. Low back pain patients were randomized of two group. Patients of the first (main) group received a course of intraosseous blockades, while patients of the second (control group) received a course ...
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova   +3 more
doaj  

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

Health Technology Assessment
Background Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this National Institute for Health and Care Excellence multiple
Nigel Fleeman, Rachel Houten, Sarah Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell   +13 more
doaj   +1 more source

From cramming to binge‐watching: Integrating documentary‐based assessment into a pharmacology and toxicology curriculum—a qualitative study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi, Heleen van der Sijs, Floor van Rosse   +2 more
wiley   +1 more source

Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа

Фармакоэкономика, 2015
The analysis goal is to determine the cost-effectiveness of liraglutideas add-on to metformin in for patients with type 2 diabetes in condition of the Russian health care system.
A. Yu. Kulikov, I. V. Novikov
doaj  

Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models [PDF]

, 2023
Matthew Franklin, Mónica Hernández Alava   +1 more
openalex   +1 more source

Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England [PDF]

, 2015
Introduction Despite recommendations that general practitioners (GPs) delay antibiotic prescribing for respiratory tract infections (RTIs), antibiotic prescriptions in primary care in England increased by 4.1% from 2010 to 2013.
Hunter, R
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Public views on principles for health care priority setting: findings of a European cross-country study using Q methodology [PDF]

, 2015
International ...
Anand, Baker, Baker, Baker, Baker, Bobinac, Boot, Brouwer, Brouwer, Brown, Brown, Brown, Buljac, Buxton, Cam Donaldson, College voor Zorgverzekeringen, Cramm, Cuppen, Cuppen, Daniels, De Graaf, Dolan, Donabedian, Donaldson, Donaldson, Donaldson, Donaldson, Eccleston, Gagnon, Gerard, Goldberg, Greiner, Guttman, Helen Mason, Hofstede, Job van Exel, Klein, Kline, Kraijo, Lancsar, Linley, Litva, Lobo, Longson, McKeown, Menon, Mooney, National Institute for Health and Clinical Excellence, Nord, Pennington, Rachel Baker, Risdon, Robinson, Schmolck, Schwappach, Scottish Medicines Consortium NS, Smith, Stenner, Stephenson, Tielen, Tsuchiya, Van de Wetering, Van Eeten, Van Exel, Vermaire, Wallenburg, Watts, Weinstein, Werner Brouwer, Williams, Williams, Williams, Williams, Wiseman   +73 more
core   +2 more sources

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source